Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Krishnan on the Optimal Use of DKd in Relapsed/Refractory Multiple Myeloma

October 11th 2024

Amrita Krishnan, MD, discusses the role of DKd for patients with relapsed/refractory multiple myeloma.

Dr Lentzsch on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

October 11th 2024

Suzanne Lentzsch, MD, PhD, discusses the safety profile of linvoseltamab in patients with relapsed/refractory multiple myeloma.

EU Approval Sought for D-VRd in Newly Diagnosed Myeloma

October 10th 2024

A Type II variation application has been submitted to the EMA for subcutaneous daratumumab plus VRd in newly diagnosed multiple myeloma.

Dr Banerjee on Future Hopes For Bispecific Antibody Therapy in Myeloma

October 8th 2024

Rahul Banerjee, MD, FACP, discusses his hopes for the future of bispecific antibody therapy for patients with multiple myeloma.

D-VRd Propels Toward SOC Status in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

October 8th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, expands on data from the CEPHEUS trial of D-VRd in transplant-ineligible/-deferred, newly diagnosed multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 9/29

October 5th 2024

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

OncLive’s September Roundup of Key FDA Approvals in Oncology

October 4th 2024

Here is your snapshot of all treatment options that the FDA approved in September 2024.

Dr Chari on the Risks and Benefits Associated With Earlier CAR T Use in R/R Multiple Myeloma

October 4th 2024

Ajai Chari, MD, discusses the potential role for CAR T-cell therapies in the early-relapsed setting for patients with multiple myeloma.

Dr Usmani on Challenges With Bispecifics and CAR T-Cell Therapies in Multiple Myeloma

October 3rd 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses challenges of integrating bispecific antibodies and CAR T-cell therapies into the community for myeloma.

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma

October 2nd 2024

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma

October 2nd 2024

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.

Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma

October 2nd 2024

Binod Dhakal, MD, discusses survival data with ciltacabtagene autoleucel in lenalidomide-refractory relapsed/refractory multiple myeloma.

Dr Corre on MRD Negativity With D-VTd Induction/Consolidation in Newly Diagnosed Multiple Myeloma

October 2nd 2024

Jill Corre, PharmD, PhD, discusses minimal residual disease negativity rates after treatment with D-VTd induction/consolidation in newly diagnosed multiple myeloma.

BPd Maintains QOL vs PVd, Supporting Its Use as a New SOC in R/R Myeloma

October 2nd 2024

No significant differences in patient-reported outcomes were observed with BPd vs PVd among patients with relapsed/refractory multiple myeloma.

Cilta-Cel Shows Real-World Feasibility and Efficacy With Acceptable Safety in R/R Myeloma

October 1st 2024

Cilta-cel elicits high response rates with an acceptable toxicity profile in a real-world population of patients with relapsed/refractory multiple myeloma.

Dr Usmani on the Efficacy of Daratumumab Plus VRd in Newly Diagnosed, Transplant-Ineligible Myeloma

October 1st 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the efficacy of daratumumab plus VRd in patients with transplant-ineligible or -deferred multiple myeloma.

Dr Badros on the Efficacy of Daratumumab Plus Lenalidomide in Newly Diagnosed Myeloma

October 1st 2024

Ashraf Badros, MBCHB, discusses the addition of subcutaneous daratumumab to lenalidomide vs lenalidomide alone in newly diagnosed myeloma following ASCT.

Cilta-Cel Prolongs OS in Lenalidomide-Refractory Multiple Myeloma

October 1st 2024

Cilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.

BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma

October 1st 2024

The GPRC5D-targeted CAR T-cell therapy BMS-986393 led to an objective response rate of 96% in patients with relapsed/refractory multiple myeloma.

Daratumumab Plus RVd as Induction Therapy Improves Responses, Survival in Newly Diagnosed Myeloma

October 1st 2024

The data are part of the largest reported cohorts of consecutive and uniformly treated real-world patients with newly diagnosed multiple myeloma.